Journal of Autoimmunity

Papers
(The TQCC of Journal of Autoimmunity is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
ArticleCitations
The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak3253
The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China600
Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?533
The etiology of rheumatoid arthritis334
The 2022 outbreak and the pathobiology of the monkeypox virus251
Autoinflammatory and autoimmune conditions at the crossroad of COVID-19223
Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19212
Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses199
Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies163
Characteristics and prognostic factors of disease severity in patients with COVID-19: The Beijing experience158
An overview of autoantibodies in rheumatoid arthritis151
Complement activation and endothelial perturbation parallel COVID-19 severity and activity117
Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection116
The pathogenesis, diagnosis and clinical manifestations of steroid-induced osteonecrosis109
Inflammatory markers in systemic lupus erythematosus98
Systemic autoinflammatory diseases97
Treg cells in health and autoimmune diseases: New insights from single cell analysis95
Metagenomic profiling of the pro-inflammatory gut microbiota in ankylosing spondylitis95
Mitigating Covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy93
Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy93
COVID-19 convalescent plasma composition and immunological effects in severe patients90
The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-1990
The pathogenesis of systemic lupus erythematosus: Harnessing big data to understand the molecular basis of lupus85
Autoimmune hepatitis triggered by SARS-CoV-2 vaccination83
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups82
SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients81
Ferritin – from iron, through inflammation and autoimmunity, to COVID-1980
The immunobiology of mTOR in autoimmunity73
Acute autoimmune-like hepatitis with atypical anti-mitochondrial antibody after mRNA COVID-19 vaccination: A novel clinical entity?71
Sjögren's syndrome: Old and new therapeutic targets70
Auto-immune hepatitis following COVID vaccination69
Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients68
The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 – A systematic review of the literature65
Autoimmune hepatitis after COVID-19 vaccine – more than a coincidence64
A case of Graves' disease and type 1 diabetes mellitus following SARS-CoV-2 vaccination61
Clinical significance of miRNAs in autoimmunity59
Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab53
Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data51
Precision medicine and management of rheumatoid arthritis51
Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-1950
Safety and efficacy of fecal microbiota transplantation for treatment of systemic lupus erythematosus: An EXPLORER trial49
Autoimmune hepatitis after SARS-CoV-2 vaccine: New-onset or flare-up?49
The roles of PPARγ and its agonists in autoimmune diseases: A comprehensive review48
The progress and prospect of regulatory T cells in autoimmune diseases47
Marginal zone B cells: From housekeeping function to autoimmunity?47
JAK/STAT signaling controls the fate of CD8+CD103+ tissue-resident memory T cell in lupus nephritis45
Recent advances in the NEK7-licensed NLRP3 inflammasome activation: Mechanisms, role in diseases and related inhibitors45
LncRNA PVT1 links Myc to glycolytic metabolism upon CD4+ T cell activation and Sjögren's syndrome-like autoimmune response44
Innate immunity as the trigger of systemic autoimmune diseases44
Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study43
Perspectives on vaccine induced thrombotic thrombocytopenia43
Resistant starch intake alleviates collagen-induced arthritis in mice by modulating gut microbiota and promoting concomitant propionate production42
A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases42
Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data42
Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-1942
High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients42
Autoantibodies to neutrophil extracellular traps represent a potential serological biomarker in rheumatoid arthritis39
Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies – A Danish population-based cohort study39
Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review38
EZH2 deficiency attenuates Treg differentiation in rheumatoid arthritis38
Mushrooms and immunity37
Evolving story of autoantibodies in systemic lupus erythematosus36
Durable antibody response one year after hospitalization for COVID-19: A longitudinal cohort study36
New developments implicating IL-21 in autoimmune disease35
Clinical disease activity and flare in SLE: Current concepts and novel biomarkers35
Extracellular vesicles and lupus nephritis - New insights into pathophysiology and clinical implications35
Leukocytoclastic vasculitis (cutaneous small-vessel vasculitis) after COVID-19 vaccination34
Cardiovascular disease risk in antiphospholipid syndrome: Thrombo-inflammation and atherothrombosis33
Innate inflammation drives NK cell activation to impair Treg activity33
Regulatory T cells in autoimmune hepatitis: an updated overview33
Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines33
Disordered cutaneous microbiota in systemic lupus erythematosus32
Abnormalities of T cells in systemic lupus erythematosus: new insights in pathogenesis and therapeutic strategies31
Loss of epigenetic modifications on the inactive X chromosome and sex-biased gene expression profiles in B cells from NZB/W F1 mice with lupus-like disease30
The pivotal role of CD69 in autoimmunity30
Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development30
Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis30
Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals29
Short-chain fatty acid butyrate induces IL-10-producing B cells by regulating circadian-clock-related genes to ameliorate Sjögren's syndrome29
Intestinal permeability in type 1 diabetes: An updated comprehensive overview29
Relapsed and newly diagnosed Graves’ disease due to immunization against COVID-19: A case series and review of the literature29
A comprehensive analysis of the clinical characteristics and laboratory features in 179 patients with autoimmune autonomic ganglionopathy28
Mesenchymal stromal cells-derived extracellular vesicles alleviate systemic sclerosis via miR-29a-3p28
Cell-autonomous epithelial activation of AIM2 (absent in melanoma-2) inflammasome by cytoplasmic DNA accumulations in primary Sjögren's syndrome28
Histone deacetylase 1 (HDAC1): A key player of T cell-mediated arthritis28
Bi-directional communication: Conversations between fibroblasts and immune cells in systemic sclerosis28
Gene expression profiling of epithelium-associated FcRL4+ B cells in primary Sjögren's syndrome reveals a pathogenic signature27
Corrigendum to “The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China” [J. Autoimmun. 109C (2020) 102434]27
Lupus nephritis: new progress in diagnosis and treatment27
Experimental evidence of pathogenic role of IgG autoantibodies in IgA nephropathy26
Pirfenidone alleviates lipopolysaccharide-induced lung injury by accentuating BAP31 regulation of ER stress and mitochondrial injury26
Cardiac involvement in adult-onset Still's disease: Manifestations, treatments and outcomes in a retrospective study of 28 patients26
CXCL4 triggers monocytes and macrophages to produce PDGF-BB, culminating in fibroblast activation: Implications for systemic sclerosis26
Profiling of the immune repertoire in COVID-19 patients with mild, severe, convalescent, or retesting-positive status25
Antagonizing miR-7 suppresses B cell hyperresponsiveness and inhibits lupus development25
Insights into the treatment of rheumatoid arthritis: A paradigm in medicine25
Severe aplastic anemia after COVID-19 mRNA vaccination: Causality or coincidence?25
Comprehensive TCR repertoire analysis of CD4+ T-cell subsets in rheumatoid arthritis25
Selective targeting of PI3Kδ suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseases24
Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors24
Multi-omics: Differential expression of IFN-γ results in distinctive mechanistic features linking chronic inflammation, gut dysbiosis, and autoimmune diseases24
Human gingiva-derived mesenchymal stem cells are therapeutic in lupus nephritis through targeting of CD39−CD73 signaling pathway24
Mutations in the monkeypox virus replication complex: Potential contributing factors to the 2022 outbreak24
Autoimmune dysautonomia in women with silicone breast implants24
Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus24
Microscopic polyangiitis: Clinical characteristics and long-term outcomes of 378 patients from the French Vasculitis Study Group Registry23
A biomarker for lymphoma development in Sjogren's syndrome: Salivary gland focus score23
Prevention and cure: The major unmet needs in the management of rheumatoid arthritis23
Insights into interplay of immunopathophysiological events and molecular mechanistic cascades in psoriasis and its associated comorbidities23
In systemic lupus erythematosus anti-dsDNA antibodies can promote thrombosis through direct platelet activation23
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort23
The complement system and human autoimmune diseases23
A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center22
Treat to target in axial spondyloarthritis: From its concept to its implementation22
LAG3 (CD223) and autoimmunity: Emerging evidence22
Integrated bulk and single-cell RNA-sequencing identified disease-relevant monocytes and a gene network module underlying systemic sclerosis22
Correction of autophagy impairment inhibits pathology in the NOD.H-2h4 mouse model of primary Sjögren's syndrome22
Resident human dermal γδT-cells operate as stress-sentinels: Lessons from the hair follicle21
Short term outcomes of COVID-19 in lupus: Propensity score matched analysis from a nationwide multi-centric research network21
Gut microbiota in systemic lupus erythematosus: A fuse and a solution21
Dendritic cells in systemic lupus erythematosus: From pathogenesis to therapeutic applications21
Monoclonal antibodies from B cells of patients with anti-MDA5 antibody-positive dermatomyositis directly stimulate interferon gamma production20
T helper cell immunity in pregnancy and influence on autoimmune disease progression20
Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study20
Transcriptome landscape of double negative T cells by single-cell RNA sequencing19
Pathogenesis, multi-omics research, and clinical treatment of psoriasis19
Rituximab plus belimumab in non-infectious refractory cryoglobulinemia vasculitis: A pilot study19
Autoantibodies in systemic lupus erythematosus: From immunopathology to therapeutic target19
Association of the CXCL9-CXCR3 and CXCL13-CXCR5 axes with B-cell trafficking in giant cell arteritis and polymyalgia rheumatica19
Insights into the knowledge of complex diseases: Environmental infectious/toxic agents as potential etiopathogenetic factors of systemic sclerosis19
CD137 / CD137 ligand signalling regulates the immune balance: A potential target for novel immunotherapy of autoimmune diseases19
0.050191879272461